

Amendments to the Specification:

On Page 1, after the title, insert the following new paragraph:

--CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Serial No. 09/921,114, filed August 2, 2001, which is a continuation of U.S. patent application Serial No. 09/518,896, filed March 6, 2000, which is a continuation of U.S. patent application Serial No. 08/987,719, now U.S. Patent No. 6,166,183, which is a continuation of U.S. patent application Serial No. 07/983,620, now U.S. Patent No. 5,824,778, which is a continuation of U.S. patent application Serial No. 07/566,451, filed October 1, 1990, abandoned, which is a 371 of PCT/JP89/01292, filed December 22, 1989, abandoned.--

Please replace the paragraph beginning at page 4, line 1, with the following amended paragraph.

Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln
Ser Phe Leu Leu Lys Cys Leu Glu Gln Val Arg
Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu
Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro
Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly
Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser
Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln
Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu
Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu
Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val
Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met
Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro
Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala
Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala

Ser His Leu Gln Ser Phe Leu Glu Val Ser Tyr
Arg Val Leu Arg His Leu Ala Gln Pro

[n = 0 (SEQ ID NO: 1) or n = 1 (SEQ ID NO:2)] --

Please replace the paragraph beginning at page 11 line 2, with the following amended paragraph.

--Recombinant human G-CSF (Japanese Patent Application Laying Open KOHYO No. 500636/88) having the following amino acid sequence (SEQ ID NO:2) was used for the chemical modification according to the present invention:--

Please replace the Abstract of the Disclosure after the claims and prior to the drawing sheets with the following:

-- ABSTRACT

The present invention provides a haematopoietic growth factor having the natural complement of lysine residues prepared by binding at least one polyethylene glycol molecule to at least one amino acid of the haematopoietic growth factor. --